HUTCHMED’s ORPATHYS plus TAGRISSO shows OS and PFS gains after TAGRISSO progression
HUTCHMED (HCM) says ORPATHYS® plus TAGRISSO® demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO®.